Importance Chronic obstructive pulmonary disease (COPD) is a common and deadly
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …

A number of agents are available for the treatment of patients with COPD. For agents whose
suggested mode of action is quite distinct (Table 1), a combination of various agents in a …

To assess awareness and understanding of obstructive airway diseases by primary-care
physicians, the authors surveyed a randomly selected population of 75 primary care …

In 2014 and 2015, more than 6% of adults aged 40 years or older reported having been
diagnosed with chronic obstructive pulmonary disease (COPD). Although the prevalence of …

Part of the success of the intervention in this study also may relate to the creation of a team,
partnering patients, caregivers, and clinicians, which was a central theme in the study …

Background Chronic obstructive pulmonary disease (COPD) is the third-leading cause of
death in the United States. Guideline recommendations for medication therapy include the …

A randomized, double-blind, placebo-controlled clinical trial was designed to assess the
safety, efficacy, and duration of the bronchodilation resulting from the addition of 500 μg of …

Background Management guidelines of chronic obstructive pulmonary disease (COPD) are
mainly based on results of randomised controlled trials (RCTs), but some authors have …

Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-
dimensional approach, taking into account both symptoms of the patient and the number of …

In the present trial, we compared the broncholytic efficacy of the combination therapy with 50
μg salmeterol+ 250 μg fluticasone and 12 μg formoterol+ 400 μg budesonide, both in a …